Phacilitate Leaders Forum

Phacilitate Leaders Europe Agenda 2018

Loading

Practical insights on market access: How viable are ATMPs from an EU payer perspective?

11-Sep-2018
Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  • Practical methods for reimbursement in a multinational network
  • How are EU payers and HTA bodies viewing these therapies from a pricing perspective? Is the clinical effectiveness of CAR-T and other ATMPs justifying the cost of treatment?
  • How will we fairly price single dose curative therapies? 
  • Can we build a new way to fund, assess and pay for these treatments together?
Speakers
Andrew Obenshain, SVP, Head of Europe - bluebird bio
Detlev Parow, Head of the Department of Medicines, Therapeutic Appliances and Remedies - DAK-Gesundheit
Marc Matar, Partner - Simon-Kucher & Partners
Thomas Fellner, Head of Cell & Gene Therapy - Lonza Pharma & Biotech
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd